Cargando…

SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer

Pancreatic cancer is characterized by a poor prognosis, with its five-year survival rate lower than that of any other cancer type. Gemcitabine, a standard treatment for pancreatic cancer, often has poor outcomes for patients as a result of chemoresistance. Therefore, novel therapeutic targets must b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Myeong Jin, Kim, Hyung Sun, Kang, Hyeon Woong, Lee, Da Eun, Hong, Woosol Chris, Kim, Ju Hyun, Kim, Minsoo, Cheong, Jae-Ho, Kim, Hyo Jung, Park, Joon Seong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605569/ https://www.ncbi.nlm.nih.gov/pubmed/37887353 http://dx.doi.org/10.3390/cells12202509

Ejemplares similares

The role of LOXL2 induced by glucose metabolism-activated NF-κB in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant PDAC
por: Lee, Yun Sun, et al.
Publicado: (2023)

Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction
por: Lee, Da Eun, et al.
Publicado: (2022)

CD74 Promotes a Pro-Inflammatory Tumor Microenvironment by Inducing S100A8 and S100A9 Secretion in Pancreatic Cancer
por: Hong, Woosol Chris, et al.
Publicado: (2023)

Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-Myc signaling pathway by inducing β-catenin ubiquitination in pancreatic cancer
por: Kang, Hyeon Woong, et al.
Publicado: (2023)

Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer
por: Yang, Jianhui, et al.
Publicado: (2021)

Radiation recall gastritis secondary to combination of gemcitabine and erlotinib in pancreatic cancer and response to PPI - a case report
por: Choi, Seong Ji, et al.
Publicado: (2016)

Intraoperative radiation therapy induces immune response activity after pancreatic surgery
por: Lee, Yun Sun, et al.
Publicado: (2021)

A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance
por: Lee, Hee Seung, et al.
Publicado: (2017)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

The role of ferroptosis regulators in the prognosis, immune activity and gemcitabine resistance of pancreatic cancer
por: Tang, Rong, et al.
Publicado: (2020)

A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
por: Lee, Hee Seung, et al.
Publicado: (2017)

Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma
por: Takagi, Tadataka, et al.
Publicado: (2023)

Antifibrotic effects of pentoxifylline improve the efficacy of gemcitabine in human pancreatic tumor xenografts
por: Kim, Jung Ho, et al.
Publicado: (2017)

Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
por: Lee, Kyung-Hun, et al.
Publicado: (2021)

The Genetic Variability of Members of the SLC38 Family of Amino Acid Transporters (SLC38A3, SLC38A7 and SLC38A9) Affects Susceptibility to Type 2 Diabetes and Vascular Complications
por: Crocco, Paolina, et al.
Publicado: (2022)

Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial
por: Lim, Sung Hee, et al.
Publicado: (2021)

Neutral amino acid transporter SLC38A2 protects renal medulla from hyperosmolarity-induced ferroptosis
por: Du, Chunxiu, et al.
Publicado: (2023)

A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer
por: Han, Boram, et al.
Publicado: (2021)

Exosomal ACADM sensitizes gemcitabine-resistance through modulating fatty acid metabolism and ferroptosis in pancreatic cancer
por: Yang, Yuhan, et al.
Publicado: (2023)

Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells
por: DUONG, HONG-QUAN, et al.
Publicado: (2012)

First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy vs combination chemotherapy
por: Han, Sung Yong, et al.
Publicado: (2020)

ADAR1-dependent miR-3144-3p editing simultaneously induces MSI2 expression and suppresses SLC38A4 expression in liver cancer
por: Kim, Hyung Seok, et al.
Publicado: (2023)

Letrozole Suppresses the Fusion of Osteoclast Precursors through Inhibition of p38-Mediated DC-STAMP Pathway
por: Kim, Hyung Joon, et al.
Publicado: (2020)

Cucurbitacin D Induces G2/M Phase Arrest and Apoptosis via the ROS/p38 Pathway in Capan-1 Pancreatic Cancer Cell Line
por: Kim, Myeong-Sun, et al.
Publicado: (2020)

Consistent Response on Challenge and Rechallenge of Liposomal Irinotecan in a Patient with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine plus Nab-Paclitaxel: A Case Report
por: Kim, Seong-Ryong, et al.
Publicado: (2021)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma
por: Park, Joo Kyung, et al.
Publicado: (2016)

The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer
por: Hage, C, et al.
Publicado: (2013)

Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients
por: Schlick, Konstantin, et al.
Publicado: (2020)

Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-X(L)–Specific Degrader DT2216
por: Thummuri, Dinesh, et al.
Publicado: (2022)

Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma
por: Rohila, Deepak, et al.
Publicado: (2023)

Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine
por: Duong, Hong-Quan, et al.
Publicado: (2013)

Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients
por: Kim, Bum Jun, et al.
Publicado: (2017)

Ferroptosis-Related Genes in Neurodevelopment and Central Nervous System
por: Kim, Soo-Whee, et al.
Publicado: (2021)

1-Cinnamoyltrichilinin from Melia azedarach Causes Apoptosis through the p38 MAPK Pathway in HL-60 Human Leukemia Cells
por: Jeong, Hoibin, et al.
Publicado: (2020)

Preoperative CT texture features predict prognosis after curative resection in pancreatic cancer
por: Kim, Hyung Sun, et al.
Publicado: (2019)

Targeting the bicarbonate transporter SLC4A4 overcomes immunosuppression and immunotherapy resistance in pancreatic cancer
por: Cappellesso, Federica, et al.
Publicado: (2022)

Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy
por: Kim, Hong Jun, et al.
Publicado: (2020)

Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost–Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study
por: Woo, Sang Myung, et al.
Publicado: (2017)

CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
por: Wasan, H S, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_n5rp0f40q83pdnmoholp99t1dp